[Purinor in the treatment of porphyria cutanea tarda].
D000225:Adenine / Q000627:therapeutic use; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D004338:Drug Combinations; D005636:Fructosephosphates / Q000627:therapeutic use*; D006801:Humans; D007042:Hypoxanthines / Q000627:therapeutic use; D007294:Inositol / Q000627:therapeutic use*; D008274:Magnesium; D008297:Male; D008875:Middle Aged; D009963:Orotic Acid / Q000627:therapeutic use*; D011164:Porphyrias / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000652:urine; D011166:Porphyrins / Q000652:urine; D011687:Purines / Q000627:therapeutic use*; D014970:Xanthines / Q000627:therapeutic use
D004338:Drug Combinations; D005636:Fructosephosphates; D007042:Hypoxanthines; D011166:Porphyrins; D011687:Purines; D014970:Xanthines; D007294:Inositol; D009963:Orotic Acid; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D008274:Magnesium; D000225:Adenine
Purinor bei der Behandlung der Porphyria cutanea tarda